Send us a text with a question or thought on this episode ( We cannot replay from this link)

What if a drop of blood or menstrual fluid could reveal the hidden biology driving endometriosis? We sit down with Dr. Canio Martinelli, OBGYN and oncology educator, to unpack how liquid biopsy is moving from bold idea to practical tool—and what it will take to make it safe, accurate, and accessible. From circulating “fingerprints” to AI-enhanced signal detection, we chart a path toward earlier detection, better monitoring, and more precise interventions.
We break the science into clear layers: genomics, epigenetics like DNA methylation, RNA transcription, and protein function. That stack of information explains why one-size-fits-all tests fall short and why a multi-omic signature could finally reflect the reality patients live with—wildly variable symptoms, misdiagnosis, and years of unanswered questions. We also tackle the stakes of accuracy. FDA-grade standards for AI diagnostics force meaningful validation so a negative result doesn’t silence someone’s pain or delay necessary care. Noninvasive testing should expand options and trust, not replace clinical judgment or a skilled surgeon when they’re needed.
Beyond diagnosis, we explore how liquid biopsy can accelerate research and drug development, enrich clinical trials with likely responders, and even enable molecular-guided surgery to remove microscopic disease more precisely. We talk equity and access through affordable sensors, transparent reporting, and patient education that demystifies what results mean. The takeaway is both practical and hopeful: rigorous science, ethical design, and patient-centered choices can change outcomes in women’s health. If this conversation gave you new language, new questions, or a new sense of possibility, follow the show, share it with someone who needs validation today, and leave a review to help more listeners find these tools and this community.

Support the show

Website endobattery.com

Instagram: EndoBattery